Late life depression

Area of Science:

• Gerontology
• Psychiatry
• Neuroscience

Background:

• Late life depression (LLD) affects 15% of individuals aged 65+, significantly increasing mortality risk.
• LLD is underdiagnosed and undertreated, with higher mortality rates following myocardial infarction and stroke.
• Age-related brain changes, neurodegenerative disorders (e.g., Alzheimer's disease), and nutrient deficiencies (folic acid, vitamin B12) are risk factors.

Purpose of the Study:

• To highlight the prevalence and risks of late life depression.
• To discuss the heterogeneous etiology of depression in older adults.
• To review current treatment strategies and their efficacy in the elderly population.

Main Methods:

• Literature review of depression prevalence, risk factors, and treatment outcomes in older adults.
• Analysis of epidemiological data on late life depression.
• Evaluation of pharmacological (SSRIs) and non-pharmacological interventions.

Main Results:

• Selective serotonin reuptuptake inhibitors (SSRIs) show a 65% response rate for depression and associated emotional disturbances.
• Comprehensive treatment, integrating social and psychological support, achieves an 80-90% response rate.
• Elderly patients face a higher risk of adverse events from depression medications.

Conclusions:

• Late life depression is a significant public health concern with serious consequences, including premature death.
• SSRIs are effective treatments, but a multimodal approach combining medication with social and psychological support yields the best outcomes.
• Early diagnosis and comprehensive management are crucial for improving the quality of life and reducing mortality in elderly individuals with depression.